These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29032739)

  • 41. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment.
    Carter KC; Gallagher G; Baillie AJ; Alexander J
    Eur J Immunol; 1989 Apr; 19(4):779-82. PubMed ID: 2786473
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral treatment with zinc sulfate increases the expression of Th1 cytokines mRNA in BALB/c mice infected with Leishmania major.
    Afshari M; Riazi-Rad F; Khaze V; Bahrami F; Ajdary S; Alimohammadian MH
    Cytokine; 2016 May; 81():71-6. PubMed ID: 26896749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis.
    Constantinescu CS; Hondowicz BD; Elloso MM; Wysocka M; Trinchieri G; Scott P
    Eur J Immunol; 1998 Jul; 28(7):2227-33. PubMed ID: 9692892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IL-18 gene therapy develops Th1-type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9?
    Li Y; Ishii K; Hisaeda H; Hamano S; Zhang M; Nakanishi K; Yoshimoto T; Hemmi H; Takeda K; Akira S; Iwakura Y; Himeno K
    Gene Ther; 2004 Jun; 11(11):941-8. PubMed ID: 14985787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The leishmanicidal activity of oleuropein is selectively regulated through inflammation- and oxidative stress-related genes.
    Kyriazis ID; Koutsoni OS; Aligiannis N; Karampetsou K; Skaltsounis AL; Dotsika E
    Parasit Vectors; 2016 Aug; 9(1):441. PubMed ID: 27501956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of CD40-induced N-Ras activation reduces leishmania major infection.
    Chakraborty S; Srivastava A; Jha MK; Nair A; Pandey SP; Srivastava N; Kumari S; Singh S; Krishnasastry MV; Saha B
    J Immunol; 2015 Apr; 194(8):3852-60. PubMed ID: 25786685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Coinfection with Listeria monocytogenes potentlxtes the response of BALB/c mice against Leishmania major.
    Tabbara KS; Al-Azmi AS; Al Salem JA
    J Egypt Soc Parasitol; 2004 Apr; 34(1):349-66. PubMed ID: 15125539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model.
    Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Rafati S
    Appl Microbiol Biotechnol; 2016 Aug; 100(16):7051-60. PubMed ID: 26960322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Homeopathic medicines cause Th1 predominance and induce spleen and megakaryocytes changes in BALB/c mice infected with Leishmania infantum.
    Cajueiro APB; Goma EP; Dos Santos HAM; Almeida Rodrigues I; Toma HK; Araújo SM; Bonamin LV; Gomes NBN; Castelo-Branco MTL; de Souza Dias EP; Dos Santos Pyrrho A; Holandino C
    Cytokine; 2017 Jul; 95():97-101. PubMed ID: 28254560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ferroportin-encapsulated nanoparticles reduce infection and improve immunity in mice infected with Leishmania major.
    Rafiee A; Riazi-Rad F; Darabi H; Khaze V; Javadian S; Ajdary S; Bahrami F; Alimohammadian MH
    Int J Pharm; 2014 May; 466(1-2):375-81. PubMed ID: 24657288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
    Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
    Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae.
    Mizbani A; Taslimi Y; Zahedifard F; Taheri T; Rafati S
    Parasitol Res; 2011 Sep; 109(3):793-9. PubMed ID: 21442256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isolation, characterization, and functional study of extracellular vesicles derived from
    Shokouhy M; Sarvnaz H; Taslimi Y; Lajevardi MS; Habibzadeh S; Mizbani A; Shekari F; Behbahani M; Torrecilhas AC; Rafati S
    Front Cell Infect Microbiol; 2022; 12():921410. PubMed ID: 35992172
    [No Abstract]   [Full Text] [Related]  

  • 57. Macrophage Polarization in Leishmaniasis: Broadening Horizons.
    Tomiotto-Pellissier F; Bortoleti BTDS; Assolini JP; Gonçalves MD; Carloto ACM; Miranda-Sapla MM; Conchon-Costa I; Bordignon J; Pavanelli WR
    Front Immunol; 2018; 9():2529. PubMed ID: 30429856
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Novel Anti-Microbial Peptide from Pseudomonas, REDLK Induced Growth Inhibition of Leishmania tarentolae Promastigote In Vitro.
    Yu Y; Zhao P; Cao L; Gong P; Yuan S; Yao X; Guo Y; Dong H; Jiang W
    Korean J Parasitol; 2020 Apr; 58(2):173-179. PubMed ID: 32418386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Leishmania tarentolae: Taxonomic classification and its application as a promising biotechnological expression host.
    Klatt S; Simpson L; Maslov DA; Konthur Z
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007424. PubMed ID: 31344033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modeling of leishmaniasis infection dynamics: novel application to the design of effective therapies.
    Länger BM; Pou-Barreto C; González-Alcón C; Valladares B; Wimmer B; Torres NV
    BMC Syst Biol; 2012 Jan; 6():1. PubMed ID: 22222070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.